A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 318 participants.

Also called NCT02973100

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 318 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02973100
  • EudraCT 2016-002494-34
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Czechia, Mexico, Poland, Puerto Rico, Romania (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02973100. Randomized; double masking; primary purpose treatment. Start 2016-12 (registry gives no type); primary completion 2017-07-15 (actual). Results posted on 2018-08-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy
Intervention (Drug)
Dulaglutide
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct02973100
Content hash
ecc2a466d3621d82f9984447d84eddbab66f3f6c2ec57035cad206e70a9ff6a2